| Name | Title | Contact Details |
|---|
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Rome Health is a comprehensive healthcare system that delivers quality, compassionate medical care for every stage of life.
Offsite Care Resources is a Sebastopol, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tarzana Treatment Centers Inc is a Tarzana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The HealthMyne Quantitative Imaging Decision Support (QIDS)® software platform and its Rapid Precise Metrics (RPM)™ functionality transform multiple clinical decision support workflows by combining quantitative imaging metrics with relevant patient information.